Immunogenicity and Duration of Immunity in Immunosuppressed Children Vaccinated With Quadrivalent HPV Vaccine

Trial Profile

Immunogenicity and Duration of Immunity in Immunosuppressed Children Vaccinated With Quadrivalent HPV Vaccine

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human polyomavirus infections
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 01 May 2017 Status changed from active, no longer recruiting to completed.
    • 25 Nov 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.
    • 09 Jul 2016 Results published in the Vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top